Bio Tech News - Biotech News

Syntaxin, a biopharmaceutical company developing novel biologic drugs that control cell secretion, today reports that Andrew Sandham has been appointed Executive Chairman.

Allergan Inc, is to initiate clinical development of a re-targeted endopeptidase drug candidate for the treatment of chronic pain.

Oxford, UK, 17 March 2008: Syntaxin Ltd, a biopharmaceutical company developing novel biologic drugs that control cell secretion, today announces the appointment of Eduard E. Holdener as Non-Executive Director with immediate effect.

Syntaxin expands its team with the appointment of Chief Medical Officer and Head of Cell Biology

Syntaxin’s new website has won a very prestigious IMA award which recognises great design, technical innovation and accessibility compliance within the interactive media industry.

Syntaxin is delighted to announce that it has secured $32 million investment as part of Series B fundraising to help advance the biologics product pipeline towards clinical proof of the novel drugs' mechanism.

Syntaxin have appointed Philip Boyd as Chief Financial Officer. Philip joins Syntaxin from Evotec AG, where he was Senior Vice President, Finance and UK Finance Director.

Syntaxin have entered into a second exclusive research and license arrangement with Allergan to design and develop novel clostridial endopeptidase-based compounds.

Syntaxin Ltd have been awarded a collaborative R&D grant of over $2.4 million from the UK Department of Trade and Industry.

Syntaxin have been launched for the discovery and development of new treatments for neurological, respiratory and metabolic diseases.